肾疏宁防治肾小球硬化机制的实验研究  

The experimental study on preventive effect of Shenshuning Mixture (肾疏宁) to glomerulosclerosis rats

作　　者：张丽芬[1] 杨洪涛[2] 何永生[2] 赵菁莉[2] 黄文政[2] 

机构地区：[1]北京中医药大学东直门医院肾病内分泌科,北京100700 [2]天津中医学院第一附属医院肾病科,天津300193

出　　处：《中药药理与临床》2006年第2期52-54,共3页Pharmacology and Clinics of Chinese Materia Medica

基　　金：天津市自然科学基金资助项目(023611511)

摘　　要：目的:观察肾疏宁防治肾小球硬化的作用机制。方法:采用单侧肾切除并阿霉素尾静脉注射建立大鼠肾小球硬化模型,观察肾疏宁给药8周后肾小球病理表现,免疫组织化学染色法观察肾小球内α-平滑肌肌动蛋白(α-SMA)、纤维连接蛋白(FN)、层粘连蛋白(LN)、Ⅳ型胶原(ColⅣ)阳性表达,并进行图像分析。结果:肾疏宁治疗组肾小球内α-SMA、FN、LN、ColⅣ和系膜基质较模型组显著减少,与苯那普利无显著性差异。结论:肾疏宁能抑制肾小球系膜细胞表型转化,减少细胞外基质蓄积,对阿霉素肾小球硬化大鼠肾脏具有保护作用。Objective： To explore the mechanism of shenshuning prevent and treat glomerulosclerosis. Method： Glomerulosclerosis model rats were induced by unilateral nephrectomy（Nx） and Doxorubicin injection, randomly divided into 4 groups, Morphological expression changes was observed by lightscope, immunochemical stain to explore the expression of α-smooth muscle actin（α-SMA） and fibronectin（FN）, liminin （LN）, collagenⅣ （ColⅣ）, and analysis with image analysis system. Results： Shenshuning can attenuate α-SMA, FN, LN, ColⅣ expression in renal tissue, decrease messangial matrix. The effective was similar with benazepril, They are significant differentiation with glomerulosclerosis group. Conclusion： Shenshuning can attenuate messangial cell transdifferentiation, decrease messangial matrix deposition, therefore protect glomerulosclerosis renal and prolong pathology development.

关 键 词：肾疏宁 肾小球硬化 系膜细胞 表型转化 

分 类 号：R285.5[医药卫生—中药学]